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Partial pathogen protection by tick-bite
sensitization and epitope recognition in
peptide-immunized HLA DR3 transgenic mice
Wendy M C Shattuck1,*, Megan C Dyer1, Joe Desrosiers2, Loren D Fast3,4, Frances E Terry5, William D Martin5,
Leonard Moise2,5, Anne S De Groot2,5, and Thomas N Mather1
1Center for Vector-Borne Disease; University of Rhode Island; Kingston, RI USA; 2Institute for Immunology and Informatics; University of Rhode Island; Providence, RI USA; 3Warren
Alpert School of Medicine; Brown University; Providence, RI USA; 4Rhode Island Hospital; Providence, RI USA; 5EpiVax; Inc.; Providence, RI USA
Keywords: epitope-based vaccine, EpiMatrix, epitope discovery, immunoinformatic, immunization, Ixodes scapularis, Lyme disease,
salivary gland, tick protective vaccine, transgenic mouse model
Abbreviations and Acronyms: TBD; Tickborne disease; tg; Transgenic; HLA DR3; Human leukocyte antigen; D related 3; B6;
C57BL/6; ATR; Acquired tick resistance; Bb; Borrelia burgdorferi; Mn; Mus musculus; SGH; Salivary gland homogenate; IFN-g;
Interferon gamma; IL-4; Interleukin-4; ConA; Concanavalin A; NPP; Naked peptide pool; LPP; Liposomal peptide pool; SFC; Spot
forming cells; NR; No response
Ticks are notorious vectors of disease for humans, and many species of ticks transmit multiple pathogens, sometimes
in the same tick bite. Accordingly, a broad-spectrum vaccine that targets vector ticks and pathogen transmission at the
tick/host interface, rather than multiple vaccines against every possible tickborne pathogen, could become an
important tool for resolving an emerging public health crisis. The concept for such a tick protective vaccine comes from
observations of an acquired tick resistance (ATR) that can develop in non-natural hosts of ticks following sensitization to
tick salivary components. Mice are commonly used as models to study immune responses to human pathogens but
normal mice are natural hosts for many species of ticks and fail to develop ATR. We evaluated HLA DR3 transgenic (tg)
“humanized” mice as a potential model of ATR and assessed the possibility of using this animal model for tick
protective vaccine discovery studies. Serial tick infestations with pathogen-free Ixodes scapularis ticks were used to tick-
bite sensitize HLA DR3 tg mice. Sensitization resulted in a cytokine skew favoring a Th2 bias as well as partial (57%)
protection to infection with Lyme disease spirochetes (Borrelia burgdorferi) following infected tick challenge when
compared to tick na€ıve counterparts. I. scapularis salivary gland homogenate (SGH) and a group of immunoinformatic-
predicted T cell epitopes identiﬁed from the I. scapularis salivary transcriptome were used separately to vaccinate HLA
DR3 tg mice, and these mice also were assessed for both pathogen protection and epitope recognition. Reduced
pathogen transmission along with a Th2 skew resulted from SGH vaccination, while no signiﬁcant protection and a
possible T regulatory bias was seen in epitope-vaccinated mice. This study provides the ﬁrst proof-of-concept for using
HLA DR tg “humanized” mice for studying the potential tick protective effects of immunoinformatic- or otherwise-
derived tick salivary components as tickborne disease vaccines.
Introduction
Ticks are found in almost every region of the world and are
second only to mosquitoes in their public health and veterinary
importance.1 However, ticks transmit the greatest variety of
human and animal pathogens of any arthropod vector, including
more than 20 emerging or Category A-C pathogens, all capable
of causing significant disease in humans.2 Few effective strategies
exist for protecting humans and animals against infection caused
by tickborne pathogens. Controlling ectoparasites of human and
veterinary importance still relies heavily on chemical pesticides;
however, effective and widespread chemical control of ticks suf-
fers from development of resistance as well as human, animal, or
environmental safety concerns.
A sound public health approach for preventing tickborne
disease (TBD) would be to develop broad-spectrum vaccines
or other effective means that target vector arthropods and the
transmission process rather than every possible tickborne
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pathogen. Since most pathogens transmitted by ticks exhibit
some form of transmission delay following attachment, a pro-
tective vaccine would need to stimulate immune responses
during the early stages of feeding, prior to or soon after path-
ogen transmission commences.1,3,4 The delay for effective
transmission of pathogens, including the Lyme disease spiro-
chete by nymphal Ixodes scapularis ticks is typically >24 hrs
and, at least in tick-bite sensitized hosts, innate immune cells
including basophils as well as CD4C (helper) T cell activity
can be activated before or soon after pathogen transmission
begins.5–7 T cells themselves are stimulated by a very limited
number of highly specific antigenic determinants (epitopes)
derived from the intruding organism’s proteins. Algorithms
that accurately model the MHC-peptide interface are central
to the prediction of T cell epitopes and are available for mice
and humans. Here, a “genes to vaccine” approach is applied
to I. scapularis tick salivary proteins for predicting epitopes
with immunogenic potential.
The concept of a tick protective vaccine has its foundation
in the naturally occurring phenomenon of acquired tick resis-
tance (ATR). Non-natural tick hosts, such as Guinea pigs and
humans, demonstrate changes in their cell-mediated and
humoral immune response upon repeat infestations with patho-
gen-free ticks.8–10 Modification of cell-mediated immunity is
characterized by migration of basophils, neutrophils and eosi-
nophils to the tick bite site with migration facilitated by T cells
and antibodies specific for tick salivary components.8,11 Recent
insights into the biology of basophils suggest their role as regu-
lators of Th2 cell responses, through IL-4 expression or the dif-
ferentiation of monocytes to macrophages.12 Th2 polarization
of the cytokine response to tick feeding has been observed both
in vitro and in vivo.13 Epidemiological and experimental evi-
dence in animals and people shows that ATR can diminish or
prevent pathogen transmission.14,15 In fact, prior work has
demonstrated that tick bite-derived ATR in the Guinea pig
results in about 50–60% protection from Borrelia burgdorferi
infection upon infected I. scapularis tick challenge.15 Unfortu-
nately, few reagents are available to fully characterize the
Guinea pig immune response to tick-bites. Repeat tick infesta-
tions in a number of laboratory mouse strains, including
BALB/c and C3H/HeN, result in significant polarization
toward a Th2 cytokine profile but without protection from
pathogen challenge or other evidence of ATR.16 It may be pos-
sible that transgenic mice, specifically those genetically altered
for human MHC II antigen presentation, could serve to fulfill
the need for an alternative model in studying the tick protective
response, as it would combine a ready availability of experimen-
tal reagents commonly exploited in mouse immunology studies
with naturally occurring ATR that correlates with B. burgdorferi
pathogen protection typically found in non-natural tick hosts.
Here, we report an evaluation of acquired tick resistance and
epitope-driven immune recognition for tick protective vaccine
development using tick-bite sensitized, whole tick salivary gland
homogenate (SGH)-immunized, and tick SGH peptide-immu-
nized HLA DR3 transgenic mice.
Results
Transgenic HLA DR3 mice as a model for acquired tick
resistance
We used 3 serial infestations with pathogen-free I. scapu-
laris nymphs to tick-bite sensitize HLA DR3 transgenic
mice and C57BL/6 mice (B6); in this study, B6 mice serve
as the genetic background control. While the HLA DR4
allele does have a greater worldwide frequency, the rationale
for using the DR3 tg mouse model is founded upon the
global distribution of HLA DR3 in Northern and Western
Europeans and its coincidence with the worldwide distribu-
tion of B. burgdorferi (Bb), the causative agent of Lyme dis-
ease.17,18 All tick sensitized mice, along with an equivalent
number of tick na€ıve controls were subsequently pathogen
challenged by infesting each animal with 3–4 nymphal I.
scapularis derived from a cohort of Bb-infected ticks. Pres-
ence of Bb was confirmed by PCR in all challenge ticks
recovered (data not shown). Tick-bite sensitized HLA DR3
tg mice exhibited a longer tick engorgement period (Table 1)
and a partial (57%) protection to Bb infection (Table 2)
when compared to tick na€ıve HLA DR3 tg mice. Moreover,
Bb copy numbers from ear-punch biopsy samples were sig-
nificantly lower (by 2.5-fold) in PCR positive, tick sensitized
HLA DR3 tg mice compared to their tick na€ıve counter-
parts. Altered tick feeding, either shortened or prolonged, is
indicative of host anti-tick responses. Grooming due to a
heightened itch response contributes to abbreviated tick
feeding.10 Prolonged feeding usually is associated with
increased pathogen transmission in tick-bite na€ıve hosts,
while extended feeding on a tick sensitized host occurs due
to an inability to obtain a proper bloodmeal. Primed host
immune defenses decrease vascular size and recruit neutro-
phils and lymphocytes to the tick bite site creating a hostile
environment for blood uptake and pathogen transmis-
sion.10,19 However, unlike ATR typically seen in other non-
natural tick hosts, there was no significant difference in the
amount of blood ingested by tick-bite sensitized HLA DR3
tg mice compared to tick na€ıve HLA DR3 or tick na€ıve or
sensitized B6 controls (Table 1).
Tick-bite sensitized HLA DR3 tg mice exhibited a cytokine
profile characteristic of a Th2 bias when compared with tick
na€ıve tg mice as demonstrated by IFNg and IL-4 ELISpot analy-
sis (Fig. 1). Splenocytes derived from tick sensitized HLA DR3
tg mice and co-cultured with SGH to stimulate a recall response
expressed 3-fold average increase in IFNg production over
background (from ¡7 § 12 to 13 § 12 spot forming cells (SFC)
over background/106 cells) when compared to na€ıve counter-
parts. However, this increase remained below our criteria for
ELISpot positivity of 50 SFC per million cells above background
and was overshadowed by a significant 40-fold greater average
SFC in the IL-4 ELISpot. IL-4 production in sensitized HLA
DR3 tg mice ranged between ¡73 § 61 to 533 § 300 SFC over
background/106 cells, a significant 8-fold increase over naive
(Fig. 1).
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Immunization studies with whole tick SGH and selected
SGH component epitopes
In a second experiment, instead of serial tick feeding to sensi-
tize HLA DR3 tg mice, we immunized mice with either whole
tick SGH or with selected T cell epitopes derived from immu-
noinformatic analysis of the I. scapularis salivary transcriptome.
Tick salivary components in the form of either whole SGH pre-
pared from 18 hr fed, pathogen-free nymphal I. scapularis or a
pool of 11 immunoinformatic-predicted CD4C T cell epitopes
were administered intra-dermally as peptides formulated in lipo-
somes (LLP) or without a carrier (NPP) and were followed by an
assessment of pathogen protection and immune recognition.
Prediction and in vitro validation of selected tick
SGH epitopes
Class II HLA epitopes were identified from the I. scapularis
salivary transcriptome using the EpiMatrix T cell epitope map-
ping algorithm combined with ClustiMer analysis.20,21 Table 3
shows the EpiMatrix cluster score for a group of epitopes selected
for synthesis because they were derived from salivary metallopro-
teases and other high abundance proteins in the transcriptome.22
Ninety percent of the selected peptides demonstrated cluster
scores >10, the threshold for predicted immunogenicity. Peptide
014 was the sole predicted epitope with a sub-threshold predic-
tive score (8.88). Despite low predicted immunogenicity, peptide
014, was sourced from a salivary protein with fibrinolytic capabil-
ities and a publication history suggesting its use as a vaccine can-
didate, and therefore was included in further testing.22,23 All 11
peptides were assayed in vitro for their capacity to bind multiple
HLA types including DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701 and DRB1*1501. Fifty-five percent of the peptides
bound to at least 3 or 4 HLA alleles, and 36% bound to all 5. Of
the 55 peptide-HLA binding interactions assayed, 53% were
strong binders with high affinity, 11% moderate binders with
mid-level affinity and 36% with low to non-detectable affinity
(Table 3). The computational predictions and binding assay
results were evaluated with classification of peptide-HLA binding
pairs as either true positive, false positive, true negative or false
negative. Positive predictions were defined as epitopes in the top
5th percentile (scoring > 1.64 on the EpiMatrix z-scale) and
binding HLA at any affinity. Overall, the agreement with predic-
tions, both positive and negative was 73%, which is consistent
with prior studies.24,25 With respect to each allele assayed, the
values are 55% for DRB1*0101, 64% for DRB1*0301, 45% for
Table 2. Infection status of B6 and HLA DR3 tg mice post Borrelia burgdorferi (Bb) challenge. qPCR results are expressed as mean § SD copies of Bb recA
genes normalized to 20,000 Mus musculus (Mn) nido genes. Figures in parentheses are minimum and maximum values. Statistical signiﬁcance (P < 0.05)
when compared to HLA DR3 na€ıve copy number denoted by *
Mouse strain Tick-bite exposure Number infected / total challenged qPCR detection of Bb
B6 Na€ıve 10/11 42.2 § 33.9 (0.0–120.2)
Sensitized 9/11 27.3 § 32.3 (0.0–103.2)
HLA DR3 Na€ıve 16/16 81.9 § 93.2 (0.0–382.7)
Sensitized 6/14 31.8 § 49.6 * (0.0–212.9) p < 0.001
Table 1. Days to engorgement and engorgement weight of Ixodes scapularis nymphs fed on B6 and HLA DR3 tg mice during repeated infestations prior to
pathogen challenge. Data are expressed as mean § SD. Figures in parentheses are minimum and maximum values. Statistical signiﬁcance (P < 0.05) when
compared to HLA DR3 primary infestation data is denoted by *
Engorgement period (days) Engorgement weight (mgs)
Infestation B6 HLA DR3 B6 HLA DR3
1st 3.9 § 0.4 3.5 § 0.8 3.2§ 1.1 3.8 § 1.0
(3.0–4.0) (1.0–5.0) (2.1–5.3) (2.3–6.1)
n D 21 n D 35 n D 21 n D 35
2nd 4.1 § 0.5 4.2 § 0.9 3.1§ 1.5 3.4 § 1.3
(3.0–5.0) (3.0–6.0) (0.4–6.0) (1.1–5.5)
n D 31 n D 36 n D 31 n D 36
3rd 4.1 § 0.5 4.2 § 0.8 3.5§ 1.0 3.3 § 1.1
(3.0–5.0) (3.0–6.0) (2.1–5.9) (1.2–4.7)
n D 32 n D 37 * n D 32 n D 37
Engorgement period (days) Engorgement weight (mgs)
Borrelia challenge: tick-bite exposure B6 HLA DR3 B6 HLA DR3
Na€ıve 4.1 § 1.1 4.1 § 1.1 3.3§ 1.7 3.8 § 1.4
(1.0–6.0) (1.0–6.0) (0.3–5.5) (0.3–5.6)
n D 36 n D 36 n D 29 n D 36
Sensitized 3.8 § 0.7 3.8 § 0.7 3.8§ 1.3 3.6 § 1.2
(3.0–6.0) (3.0–6.0) (1.5–5.9) (2.0–5.6)
n D 28 n D 28 n D 26 n D 28
3050 Volume 10 Issue 10Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
1:1
4 0
8 O
cto
be
r 2
01
5 
DRB1*0401, 64% for DRB1*0701, and 91% for DRB1*1501.
Discrepancies between positive predictions and actual binding
include peptide folding, peptide aggregation under assay condi-
tions, or the predictive accuracy of immunoinformatic algo-
rithms. A large, retrospective comparison of the EpiMatrix with
epitope mapping algorithms in the public domain showed that
EpiMatrix was >75% accurate across all the HLA Class II alleles
studied here, which is as accurate as or more accurate than other
epitope prediction tools.26 It is likely that a significant part of the
discrepancy between predictions and HLA binding is due to pep-
tide design and physical properties.
Borrelia pathogen challenge of SGH and epitope-immunized
transgenic mice
Neither SGH- nor epitope-immunized HLA DR3 tg mice
were completely protected from Bb infection when challenged by
Bb-infected ticks and compared with control vaccinated animals.
Although 100% infection rate is the “expected” outcome of the
challenged control animals, observed results differed for the aber-
rant mouse due to uncharacteristic and excessive grooming result-
ing in early removal of ticks. The majority of mice in each
vaccination arm did have detectable levels of Bb genes in ear
punch biopsies (Table 4). However, similar to the tick-bite sensi-
tized HLA DR3 tg mice, the level of Bb infection in the SGH-
vaccinated mice as measured by qPCR Bb gene copy number was
significantly lower (p D 0.038). Bb copy numbers within control
vaccinated mice were 14-fold greater (55.9§ 68.4) than the aver-
age 3.9 § 4.7 copies detected in SGH-vaccinated HLA DR3 tg
mice. NPP- and LPP-immunized mice exhibited mean Bb gene
copy numbers of 22.1 § 30.9 and 34.4 § 23.1, respectively
(Table 4). All SGH- and peptide-immunized mice had at least 2
infected challenge ticks that attached and fed for longer than 24
hrs, which is adequate to assure Bb transmission.7
Epitope-specific IFNg and IL-4 responses in tick-bite
sensitized transgenic mice
To begin dissecting the nature of the immune response to tick
salivary components, splenocytes from both tick na€ıve and tick-
bite sensitized HLA DR3 tg mice were evaluated for antigen-spe-
cific immune recall. Cells were stimulated with either whole
SGH or individual peptides for measurement of IFNg and IL-4
production by ELISpot assay. Only 2 peptides stimulated a dif-
ferential response in tick sensitized mice when compared with
their tick na€ıve counterparts (Fig. 2). Peptide 014 appeared to
stimulate IFNg production greater than 50 SFC per million sple-
nocytes in sensitized HLA DR3 tg mice (Fig. 2A) with a 3-fold
increase of 20 § 14 mean SFC over background in na€ıve mice to
81 § 13 in tick sensitized mice. However, this epitope was pre-
dicted to be a weak/non-binder for HLA DR3 (Table 3) and
may represent a spurious result. Differential IL-4 production
among tick sensitized mice was only observed for peptide 017
(Fig. 2B). Interestingly, tick sensitized mice demonstrated a sig-
nificant decrease in production of IL-4, with a mean of ¡7 § 30
SFC over background compared to a mean of 79 § 42 SFC for
tick na€ıve mice. While we did expect to see a greater number of
individual peptide stimulations result in more robust IL-4 pro-
duction among tick-bite sensitized mice, similar to what was
observed following whole SGH stimulation (Fig. 1), from these
results we can speculate that tick-bite sensitization stimulates T
cells with different epitope specificities, and that the epitopes
selected for this trial were not immunodominant.
IL-4 production in SGH- and peptide-immunized
transgenic mice
To better determine the antigenic potential of in silico-pre-
dicted tick SGH epitopes, individual peptide stimulations were
screened by IL-4 ELISpot assay, as above, but using splenocytes
derived from control-, whole SGH- and peptide-immunized
HLA DR3 tg mice prior to pathogen challenge. Splenocytes
from SGH-immunized mice restimulated with SGH demon-
strated >6-fold increase in IL-4 production compared with con-
trol-vaccinated mice (P D 0.015) (Fig. 3). Specifically IL-4
production in control HLA DR3 tg mice exhibited a mean of
¡48 § 78, while cytokine production in SGH-immunized mice
peaked at 669 SFC with mean IL-4 production of 259 § 263
SFC. Stimulation of splenocytes from SGH-immunized mice
using either the peptide pool or individual peptides yielded mini-
mal production of IL-4, never greater than 50 SFC per million
typically considered to be a positive response.
Figure 1. Ex vivo recall IFNg and IL-4 responses stimulated by salivary
gland homogenate (SGH) in tick na€ıve () and tick-bite sensitized ()
HLA DR3 tg mice. SGH was assayed for T cell reactivity by IFNg and IL-4
ELISpot assay using splenocytes isolated from mice. Data are the mean
spot-forming cells (SFC) over background per million splenocytes that
secrete cytokines in response to SGH. Individual subject average
responses are represented by dots and the mean cytokine responses
across all subjects by white bars. The 50 SFC over background per million
splenocytes cutoff is denoted by the dotted line. Statistical signiﬁcance
(P < 0.05) is noted by *.
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In mice immunized using the peptide pool (LPP and NPP),
re-stimulation using either the peptide pool or individual pepti-
des resulted in mean IL-4 production greater than 50 SFC per
million for 8 out of 11 (73%) individual epitopes as well as the
peptide pool, although results varied somewhat depending on
whether the peptides were incorporated into liposomes (LPP) or
were immunized as naked peptides (NPP)(Fig. 3). Recognition
of the peptide pool yielded a significant 6-fold increase in pro-
duction of IL-4 (mean D 194 § 177 SFC) in NPP-immunized
mice when compared to the SGH-immunized arm (P D0.005).
In individual peptide stimulations, epitopes 003, 004, 014, 017,
018, 022, 023 and 024 all stimulated a mean greater than 50
SFC per million cells in LPP-vaccinated HLA DR3 tg mice,
while only 3 of these 11 epitopes (004, 017 and 023) stimulated
a mean more than 50 SFC per million cells in NPP-vaccinated
mice, suggesting that peptide formulation in liposomes enhanced
immunogenicity. One of these epitopes, 004, produced
3£ increased SFC (mean D 98 § 28 SFC) in LPP-vaccinated
mice than in SGH-vaccinated mice (mean D ¡51 § 85 SFC),
which was a significant result (P D0.023). Peptide 004 was pre-
dicted to be a strong HLA DR3 binder. Five of the 8 epitopes
that produced greater than 50 SFC per million in LPP-vaccinated
mice were predicted to be either strong or moderate HLA DR3
binders, validating HLA binding as a pre-screening tool for epi-
tope selection in future tick protective vaccine studies using HLA
transgenic mice. Interestingly, mice immunized with the peptide
pool either with and without liposomal carrier, did not respond
to stimulation with whole SGH.
Three peptides (005, 006, and 019) failed to stimulate any
significant IL-4 responses. The small cohort size of the study and
restricted HLA background may explain this result. Alternatively,
these sequences may stimulate helper T cell cytokines other than
IL-4.
Cytokine profile of SGH and peptide-immunized
transgenic mice
Concurrent characterization of TH1/TH2/TH17 cytokine
profiles of immunized mice following prolonged (24, 48 and 72
hrs) co-culture with ConA, SGH and pooled peptides was
assayed by cytokine bead array. Figure 4 displays 48 hr co-culture
data which appeared to be the optimal incubation timepoint for
cytokine expression. Co-culture with stimulants for 72 hrs
resulted in little to no response possibly because of cell exhaustion
due to prolonged stimulant exposure (data not shown). Co-cul-
ture with ConA served as positive control for this assay and
although results varied for each cytokine in the panel (lowest IL-
4 @ 16 pg/mL; highest IFNg @ 260 pg/mL), for every cytokine
assayed, concentrations (pg above background) were consistent
between each of the experimental arms (data not shown).
Not surprisingly, Th2-associated cytokines IL-4 (6 pg/mL)
and TH17-predominant IL-6 (62 pg/mL) were the main cyto-
kines stimulated by SGH in SGH-immunized HLA DR3 tg
mice, comprising 98% of the overall response in this vaccination
arm (Fig. 4A). Mean IL-6 production stimulated by SGH in the
SGH-immunized mice was 41-fold greater than the control
immunization group while mean IL-4 production was 6-fold
greater than in the control vaccine arm. IL-10 (20 pg/mL) and
TNF (12 pg/mL) were the dominant cytokines expressed by
NPP-vaccinated mice when re-stimulated with SGH representing
60% of the overall response (Fig. 4A). The remainder of the
overall cytokine response stimulated by SGH in NPP-immunized
Table 4. Infection status of SGH- and peptide-vaccinated HLA DR3 tg mice post Borrelia burgdorferi (Bb) challenge. qPCR results are expressed as mean§ SD
copies of Bb recA genes normalized to 20,000 Mn nido genes. Figures in parentheses are minimum and maximum values. Statistical signiﬁcance (P < 0.05)
when compared to control vaccinated HLA DR3 tg mice copy number denoted by *
Vaccination Arm Number infected / total challenged qPCR detection of Bb
Control 3/4 55.9 § 68.4 (0.0–176.9)
SGH 3/4 3.9 § 4.7 * (0.0–11.1)
Peptide Pool (NPP) 4/4 22.1 § 30.9 (0.0–72.8)
Liposomal Peptides (LPP) 4/4 34.4 § 23.1 (0.0–63.3)
Table 3. HLA DR binding afﬁnities for selected immunoinformatic-predicted
Ixodes scapularis salivary epitopes. Coded peptide identiﬁers and predicted
immunogenicity (EpiMatrix cluster score) are noted in the ﬁrst 2 columns,
respectively. Column 4, *0301, represents the allele found in the DR3 trans-
genic mouse model. IC50 values in mM units were calculated from curves ﬁt-
ted to dose-dependence competition binding data for each peptide-HLA
DR allele pair. Peptide binding afﬁnity is shown according to the following
classiﬁcation: IC50 < 10 mM (black), 10 < IC50 < 100 mM (dark gray), IC50 >
100 mM (light gray)
Peptide 
EpiMatrix 
Cluster
Score
HLA CLASS II Allele IC50 
*0101 *0301 *0401 *0701 *1501 
003 36.44 
004 22.48 
005 21.82 
006 19.61 
014 8.88 
017 29.86 
018 26.17 
019 25.2 
022 24.04 
023 18.96 
024 18.27 
Weak/Non Binder     
IC50>100 
Moderate  Binder  
10<IC50<100 
Strong Binder       
IC50<10 
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mice was generally distributed across the other cytokines assayed.
SGH-stimulated cells from either control or LPP-vaccinated
mice expressed little to no response in the CBA assay.
The predominant peptide pool-stimulated cytokine response
in cells from peptide-vaccinated mice was IL-10 which comprised
37% of the total measured cytokine response in NPP-vaccinated
(25 pg/mL) mice and 76% of the response in LPP-vaccinated
mice (32 pg/mL). The remainder of the overall cytokine response
stimulated by the peptide pool was fairly evenly distributed across
the other cytokines assayed. Peptide pool-stimulated cells from
either control or SGH-vaccinated mice expressed little to no
cytokine response.
Discussion
Since its discovery by Trager in 1939,
acquired resistance to tick feeding has been
extensively studied in laboratory animals.27
Repeated tick infestations of Guinea pigs
and various murine strains act as separate
puzzle pieces that when combined, provide
an expanding picture of the features of tick-
host interactions. Traditionally ATR was
identified by the effect on the tick: altered
feeding duration, decreased engorgement
weight, reduced production and viability of
ova, and inhibition of molting.28 Observa-
tions of ATR in the Guinea pig model also
has provided insight into the role of baso-
phils at the host cutaneous bite site.8 Even
more, partial protection from Borrelia chal-
lenge seen in tick sensitized Guinea pigs
provided evidence that potential vaccine
candidates reside in the complex cocktail of
tick saliva.15 Though first identified in
Guinea pigs, the Th2 bias of repeated tick
infestations was best represented by gene
expression and cytokine profile studies in
BALB/c, C3H/HeN and C3H/HeJ murine
strains. 29-32 However, in those mouse
models, repeat tick exposure induced
immune response changes but neither
BALB/c nor C3H/HeN mice developed
resistance.16,33-35
Here, we have presented data that sup-
ports adding HLA DR3 transgenic mice to
the list of model organisms for acquired tick
resistance and tick protective vaccine discov-
ery research. Of course, further characteriza-
tion of these “humanized” transgenic mice
exposed to repeat tick infestations is needed,
including expanding the model to include
other transgenic (e.g., DR4) murine strains.
Future studies could examine the effects of
ATR in HLA tg mice on molting success and
egg production but most certainly should
include a deeper characterization of the
CD4C T cell response to tick salivary com-
ponents. Assessing the role of antibodies to tick salivary proteins,
especially IgE, and characterizing cellular infiltrates at the tick bite
site would likely yield additional immune correlates to the nearly
60% protection against Bb infection that we recorded. However, the
strong Th2 bias present in the tick-bite sensitized IL-4 ELISpot stud-
ies linked with our observed 57% protection from Borrelia pathogen
challenge, suggests that the HLA DR3 tg mouse model appears
capable of bridging the previously useful Guinea pig ATR model
and well-established murine models commonly used in immunol-
ogy and early vaccine discovery studies. The off-the-shelf availability
of resources and reagents for the murine model is one compelling
Figure 2. Ex vivo recall IFNg (A) and IL-4 (B) cytokine responses in tick na€ıve () and tick-bite sensi-
tized () HLA DR3 tg mice stimulated by SGH and individual tick salivary peptides predicted by
immunoinformatics. Data are the mean spot-forming cells (SFC) over background per million sple-
nocytes that secrete cytokines in response to SGH or individual epitopes in IFNg and IL-4 ELISpot
assays. Individual subject average responses are represented by dots and the mean cytokine
responses across all subjects by white bars. The 50 SFC over background per million splenocytes
cutoff is denoted by the dotted line. Statistical signiﬁcance (P < 0.05) is noted by *.
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reason for adopting “humanized” mice for
tick protective vaccine development studies.
Moreover, the presentation of humanMHC
II antigen in the context of the mouse model
brings the HLA DR3 tg mouse model closer
to the human perspective, which is an added
benefit for vaccine discovery research.
As noted above, any vaccine-mediated
tick protective response would likely need
to be stimulated during the early stages of
tick feeding, prior to or soon after patho-
gen transmission commences.1,3,4 With
this key concept in mind, splenocytes from
tick-bite sensitized and SGH- or peptide-
vaccinated HLA DR3 mice were re-stimu-
lated with SGH that had been prepared
from salivary glands harvested from
nymphal I. scapularis early (18 hr) in the
tick feeding process. Additionally, during
immunization studies, tg mice were immu-
nized with 18 hr SGH. Salivary gland dis-
section and collection parameters are
noteworthy due to the dynamic nature of
gene expression in the tick salivary tran-
scriptome, and the desire to concentrate
on vaccine candidates present during early
feeding, prior to pathogen transmission.
Previous studies have even suggested that
tick salivary proteins expressed prior to 24 hrs are sufficient to
induce, at least a partial tick protective immunity. 5,7,36
Empirical evidence of ATR in Guinea pigs subjected to repeat
infestations with the tick Rhipicephalus sanguineus, demonstrated
that experimental tick infestations were superior to vaccination
with unfed, crude, whole tick extract.37 Likewise, our own studies
showed that the protective response to Bb pathogen challenge fol-
lowing immunizations with 18 hr SGH proved not as effective as
when induced by repeat I. scapularis infestations. Tg mice immu-
nized with SGH did have significantly fewer copies of Bb in ear
punch biopsies than control animals, but the pathogen infection
rates between the 2 groups of animals were similar. The IFNᵧ ELI-
Spot assays documented 3x more spots over background in tick-
bite sensitized mouse splenocytes re-stimulated with SGH when
compared to their control counterparts. The IFNᵧ response of tick-
bite sensitized DR3mice, though significant, is eclipsed when com-
pared to the 40-fold higher average IL-4 response to co-culture with
SGH. Differential production of IL-4 between tick-bite sensitized
and tick-bite na€ıve DR3 mice showed >8 -fold difference using
similar assay conditions. The lower level of protection (reduced Bb
gene copy numbers, Table 4) afforded by SGH-vaccination also
was correlated with the well documented Th2-polarized cytokine
response to tick saliva. We noted by CBA, increased levels of IL-4,
IL-10 and IL-6 in SGH-immunized co-cultures in agreement with
Titus’s review of the immune-modulatory factors of I. scapularis
saliva.38 We also demonstrated that, in the best case, 8/11 epitopes
drawn from the I. scapularis salivary transcriptome stimulated an
IL-4 recall response post peptide pool-vaccination (LPP). Albeit,
the extent of Th2 polarization and pathogen protection by SGH or
peptide vaccination was inferior to that seen in experimental tick-
bite sensitizations, this study is proof of concept that in searching
for a tick protective vaccine, the transgenic mouse model is worth
exploring further with immunoinformatic-predicted tick salivary
epitopes.
The cytokine response in peptide-vaccinated mice was not
coordinated into a distinct Th1 or Th2 response as evident in the
multiplex CBA data (Fig. 4). This non-polarized, IL-10 domi-
nant immune response to peptide immunizations may explain
the lack of protection upon pathogen challenge. Indeed, the
CBA data from NPP-immunized mice co-cultured with pooled
peptides (Fig. 4B) suggests conflicting immune responses driven
by anti-inflammatory cytokine IL-10 and pro-inflammatory IL-
4, IL-6 and TNF. It is highly likely that a different pool of tick-
derived peptides would yield a cytokine profile that is Th2-
focused. Since our findings point to a Th2 correlate of protection
with a predominant IL-4 cytokine response, future studies will
focus on identifying and immunizing the HLA DR3 tg mice
with peptides that drive a more robust IL-4 response.
Increased production of IL-10 in response to tick saliva is a well
characterized aspect of repeat tick infestations.31,39 Our data in the
HLA DR3 mouse supports and expands these findings showing
high levels of IL-10 production in NPP-immunized mice in
response to co-culture with SGH as well as the peptide pool
(Fig. 4A and B). IL-10 is a multifunctional anti-inflammatory cyto-
kine that dampens the inflammatory response and helps prevent tis-
sue damage. Its role in a T regulatory manner has been suggested
Figure 3. Antigen-speciﬁc HLA DR3 tg mouse IL-4 responses stimulated by tick SGH and immu-
noinformatics-predicted tick salivary epitopes in control-, SGH-, and peptide-vaccinated mice.
Whole SGH, peptide pool and individual epitopes were assayed for T cell reactivity by IL-4 ELISpot
assay using splenocytes isolated from vaccinated mice. Data are the mean spot-forming cells (SFC)
over background per million splenocytes that secreted cytokines in response to antigen-speciﬁc
stimulation. Individual subject average responses from experimental vaccination arms are repre-
sented as: control immunizations (&), SGH immunizations (), naked peptide pool (NPP) immuni-
zations (~), liposomal peptide pool (LPP) (5). The mean cytokine responses across all subjects are
represented by white bars. The 50 SFC over background per million splenocytes cutoff is denoted
by the dotted line. Statistical signiﬁcance (P < 0.05) is noted by *.
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only recently during transcriptional profiling of repeat tick infesta-
tions of BALB/c mice in which up-regulation of IL-10 and FoxP3
was monitored at the tick-bite site 29. It may be that immunizations
with the selected immunoinformatic-derived peptides induced a T
regulatory response, accountable for the considerable IL-10 accu-
mulation and lack of protection from pathogen challenge. One par-
ticular peptide within the pool, peptide 017, with its significantly
lower IL-4 production in tick-bite sensitized tg mice compared to
na€ıve mice (Fig. 2B) suggests a potential regulatory function which
may have influenced the immunization results. Post hoc in silico
analysis of this epitope for possible TCR-face homology with
human (self) sequences was performed using JanusMatrix, a novel
algorithm developed after the tick salivary antigen epitopes were
identified.40 JanusMatrix parses the amino acid sequence of T cell
epitopes into TCR-facing residues and
HLA-facing residues, and then compares
the TCR face to other putative T cell epit-
opes in the human genome. JanusMatrix
defines cross-reactive T cell epitopes as
those that have the same MHC allele
restriction, the same or similar T cell-fac-
ing residues (epitope), and conserved
binding of MHC-facing residues (agre-
tope).40 JanusMatrix analysis reveals that
there are 9-mers in peptide 017 that share
a TCR face with 10 human 9-mers. How-
ever, this analysis should be viewed conser-
vatively, since JanusMatrix screens for
homology against the human and not the
murine genome. Regardless, the potential
T regulatory role of tick saliva and salivary
components is an interesting and likely
necessary new frontier requiring consider-
ation in going forward with tick protective
vaccine research in both the novel HLA
DR3 tg mouse model and humans. The
JanusMatrix algorithm makes it possible
to pre-screen candidate sequences for
potential Treg activation to carefully select
tick salivary protein epitopes that will sup-
port a Th2-focused immune response for
better epitope-based vaccine design in the
future.
Methods
Predicting immunogenic peptides
from the I. scapularis salivary
transcriptome with EpiMatrix and
ClustiMer analysis
EpiMatrix is a T cell epitope-mapping
algorithm used to identify putative HLA
ligands/T cell epitopes contained within
protein sequences (e.g., epitopes identi-
fied from pathogen genomes).41,42
Unlike previous EpiMatrix analyses of
genomes, the tick salivary transcriptome was used as the input
sequence and subsequent source of epitope peptides.21 Computa-
tion was performed by using a set of HLA allele-specific coeffi-
cient matrices. To complete an analysis using the EpiMatrix
algorithm, target protein sequences were parsed into overlapping
9-mer frames in which each frame overlaps the last by 8 amino
acids. Each amino acid in the 9-mer was then assigned a positive
or negative coefficient based on its previously determined pro-
pensity to positively or negatively impact peptide binding when
located at that amino-acid position within the HLA-binding
groove.43 The coefficients were then summed to produce a raw
score for each 9-mer. Raw scores were normalized with respect to
a distribution derived from a large set of randomly generated
Figure 4. Multiplex cytokine bead array (CBA) proﬁle of splenocytes from vaccinated HLA DR3 tg
mice co-cultured for 48 hrs either with whole SGH (A) or the tick salivary epitope peptide pool (B)
used in 2 of the experimental vaccination arms. Data are concentrations of cytokines in picograms
(pg/mL) above background elicited by splenocytes in response to antigen-speciﬁc stimulation. Values
of zero are represented below the x-axis as no response (NR). Vaccination arms are represented as:
Control vaccination arm- lightest gray, SGH immunization arm- white, NPP vaccination arm- dark
gray, LP immunization arm- black. Control splenocytes were co-cultured with medium C adjuvant
alone resulting in cytokine production below 12 pg/mL for all monitored cytokines (data not shown).
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peptide sequences. The resulting Z-scores from this distribution
were directly comparable across predictions for different alleles.
ClustiMer identified “clustered” or promiscuous epito-
pes.44,45 Potential T cell epitopes are not randomly distributed
throughout protein sequences but instead tended to “cluster” in
specific regions. T cell epitope “clusters” range from 9 to
roughly 25 amino acids in length and, considering their affinity
to multiple alleles and across multiple frames, could contain
anywhere from 4 to 40 binding motifs. Class II epitope selec-
tions for vaccine design were usually limited to selected
“promiscuous epitopes” – epitopes that had the potential to be
recognized in the context of more than one HLA. EpiMatrix
ClustiMer scores above 10 were considered to be immunogenic.
Peptide synthesis and HLA binding assay
All peptides used in this study were synthesized by 9-fluoro-
nylmethoxy-carbonyl (Fmoc) synthesis to a purity of >80% as
determined by HPLC by 21st Century Biochemicals (Marlbor-
ough, MA, USA). The peptide masses were confirmed by
MALDI-TOF mass spectrometry.
Peptides were assayed for HLA affinity in a competition bind-
ing assay based on Steere et al.46 In 96-well plates, a test peptide
and a reference peptide compete for binding to a purified class II
HLA molecule (Benaroya Research Institute) for 24 h at 37C.
Non-biotinylated test peptides were evaluated over a wide range
of concentrations (0.01–200 mM) while biotinylated standard
peptide was held at a fixed concentration (0.1 mM). Peptide-class
II HLA complexes were then captured on ELISA plates using pan
anti-HLA-DR antibody (L243, BioXCell). Plates were washed
and incubated with Europium-labeled streptavidin (Perkin-
Elmer) for one hour at room temperature. Europium activation
buffer was added to develop the plates for 15–20 min at room
temperature before they were read on a Time Resolved Fluores-
cence (TRF) plate reader. All assays were performed in triplicate.
Dose dependence curves were generated by fitting data using the
4-parameter logistic equation, and IC50 values were calculated in
SigmaPlot 11.0 (Systat). Based on the IC50 values, peptide bind-
ing to a given HLA allele was classified as high affinity (1–
10 mM), moderate affinity (10–100 mM), low affinity
(>100 mM). Peptides that did not inhibit the binding of the bio-
tinylated reference peptide at any concentration were considered
non-binders. Binding assays were performed for 5 alleles:
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, and
DRB1*1501, providing a broad representation of class II HLA
allele binding pockets.47
Experimental animals
Six to 14 week-old female C57BL/6 mice (B6) were pur-
chased from Harlan. HLA DR3 transgenic mice on a C57BL/6
background were obtained from Dr. Chella David (Mayo Medi-
cal School) under MTA. The mice express the HLA DR3a and
b genes on a B.10-Ab0 mouse background and were back-crossed
over 6 generations with class II-negative on a C57BL/6 back-
ground.48 Specifically, DRBI*0301 (DR3) transgenic mice were
generated by co-injection of an HLADRa genomic fragment and
a DRB1*0301b gene fragment into (C57BL/6 X DBA/2)F1 X
C57BL/6 embryos and backcrossed to B10 mice as detailed pre-
viously.49 The DR3 transgene was first introduced into B10.M
mice at the Mayo Clinic by repeated backcrossing. Subsequently,
the DR3 gene was introduced into the class II-negative H2A0
strain by mating the B10.M-DRBI*0301 line with the B10.Ab0
line, similar to the strategy detailed previously for HLADQ trans-
genic mice.50,51 All studies were performed in full compliance
with the standards of the University of Rhode Island Institutional
Animal Care and Use Committee and in accordance with NIH
publications entitled “Principles for Use of Animals” and “Guide
for the Care and Use of Laboratory Animals.”
Tick rearing and salivary gland homogenate
Ixodes scapularis ticks were reared using standard methods.4
Adult ticks were collected from nature to create immature tick col-
onies. One hundred larvae from each egg batch were screened by
PCR using pathogen-specific primers for Borrelia burgdorferi and
Borrelia miyamotoi. Certified pathogen-free larval stage ticks were
blood fed on hamsters or white-footed mice. To generate Bb-
infected nymphs, pathogen-free larvae were allowed to feed on
white-footed mice previously infected with the B31 strain of B.
burgdorferi, and were then held until molting. Such methods gen-
erally yield >90% Bb infectivity. All unfed ticks were maintained
at 23C and >90% relative humidity under 14 h light/10 h dark
photoperiod before infesting hosts. Methods for generating and
maintaining Bb-infected and uninfected tick colonies, including
animal care, followed approved URI IACUC protocols.
Pathogen-free nymphs were allowed to feed for 18–20 hours
prior to dissection for salivary glands. Partially fed ticks were dis-
sected in ice-cold phosphate buffered saline (PBS) within 4 hrs of
being removed from the host animal. After removal, glands were
washed in the clean buffer and tissues were stored at¡70C in PBS
until cell lysis by sonication. Protein concentration was detected by
UVnanodrop quantification (ThermoScientific, ND-1000).
Tick-bite sensitizations
Tick-bite sensitizations
Prior to each infestation, animals were anesthetized by IP
injection of ketamine (20mg/mL) (Vedco, NDC50989-161-06)
and xylazine (2mg/mL) (Lloyd Laboratories, 4821) and placed in
stainless steel, quarter-inch wire mesh tubes for up to 3 hours.
Tick attachment was assessed by counting attached ticks 2 hrs
after placement. At this time, all but 3 attached ticks were
removed in an effort to minimize “sharing” of tick salivary
immunosuppressive proteins. By selective removal, the 3 ticks
that remained attached were distributed as far apart as possible. A
total of 14 HLA DR3 and 11 B6 mice were sensitized to tick
bites 3 times using pathogen-free nymphs attached for 72 hrs.
Tick feedings occurred at 2 week intervals. Additionally, groups
of 16 HLA DR3 and 11 B6 mice acted as non-tick sensitized
(tick na€ıve) controls. Biologic data related to tick feeding
(engorgement weight and days to engorgement) were analyzed by
Kruskal-Wallis ANOVA of Variance on Ranks and the means
compared by Dunn’s test (P < 0.05) (SigmaPlot).
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Pathogen challenge
Two weeks following the 3rd infestation, mice, including
na€ıve controls, were challenged with 3 Bb-infected nymphs. All
animals were monitored daily, and tick feeding parameters (dura-
tion of attachment, total recovered engorged, and engorgement
weight) were recorded. Animals subjected to Bb challenge were
allowed to rest for 4 weeks to allow for dissemination of bacteria.
Detection of Borrelia infection
The Bb infection status of each animal was assessed 4 weeks
following infected tick challenge by direct PCR assay of ear
punch biopsy. Positive infection status of an animal was deter-
mined if Borrelia specific genes were amplified from ear punch
samples by quantitative PCR.
Total genomic DNA was extracted from ear punches using the
DNeasy Blood and Tissue kit (Qiagen, 69504) according to
manufacturer’s protocol. Additionally, DNA was extracted from
a non-infected mouse ear punch and a culture of Bb strain B31
for qPCR standard generation. Primers amplifying mouse nido
were used as a reference gene during simultaneous detection of
Bb recA gene. The oligonucleotide primers used to detect mouse
nidogen were nido.F 50-CCA GCC ACA GAATAC CAT CC-30,
and nido.R 50-GGA CT ACT CTG CTG CCATC-30.52 The
oligonucleotide primers used to detect Bb recA were nTM17.F
50-GTG GAT CTATTG TAT TAG ATG AGG CTC TCG-30
and nTM17.R 50-GCC AAA GTT CTG CAA CAT TAA CAC
CTA AAG-30.53 Real-time quantitative PCR (qPCR) was per-
formed using an Mx4000 Multiplex Quantitative PCR System
(Stratagene, La Jolla CA). Quantitation of DNA copy number
was performed using Brilliant SYBR Green qPCR Master Mix
(Agilent, 600828) with 10 ng of total DNA in 50 ml reactions.
Thermal profile was 95C for 15 min then 40 cycles of 95C for
30 s and 55C for 1 min and 72C for 1 min. Fluorescence was
measured at the end of the 55C step every cycle. Samples were
run in experimental duplicate with inter-plate and no template
controls. SYBR threshold was locked at 0.010 with ranges of effi-
ciency between 95–100%. Copies of Bb recA genes were normal-
ized against 20,000 copies of mouse nido genes. Samples were
determined to be unifected if no Bb recA genes were detected in
either duplicate, as indicated by “No CT value." Positive infec-
tion status was recorded if Bb recA genes were identified in either
one or both duplicates. Copy number data were analyzed by
Kruskal-Wallis ANOVA of Variance on Ranks and the means
compared by Dunn’s test (P < 0.05) using SigmaPlot software.
ELISpot detection of cytokine production in HLA DR3 tg mice
The frequency of epitope-specific splenocytes was determined
by IFNgand IL-4 ELISpot assay using the Mabtech IFN-gamma
(Mabtech, 3321–4HPT-4) or IL-4 (Mabtech, 3311–2HW-Plus)
ELISpot Kits according to the manufacturer’s protocol (Marie-
mont, OH). Briefly, spleens were harvested from groups of naive
and sensitized HLA DR3 transgenic mice and mascerated to pro-
duce single cell splenocyte suspensions in RPMI–10% (Fisher,
SH30027 FS) fetal bovine serum–1% (Thermo Scientific,
SH3007003HI) penicillin/streptomycin–1% (Lonza, 17602E) L-
glutamine–0.1% (MP Biomedicals, 091680149) and BME
(Sigma Aldrich Aldrich, M6250–10ML) at a concentration of
1.5 £ 106 cells/mL. Cells were transferred at 1.5 £ 105/well to
ELISpot plates pre-coated with anti-murine IFN-gamma by the
manufacturer. IL-4 plates were not pre-coated and were prepared
24 hrs in advance according to manufacturer’s specification. Cells
were stimulated with SGH at 20 mg/mL in triplicate wells and
individual peptides at (20 mg/mL also in triplicate). Cells co-cul-
tured with ConA (2 mg/ml) (Sigma Aldrich, C5275–5MG)
acted as positive controls while cells stimulated with no peptide
(PBS only) served as a negative control. ELISpot plates were
incubated at 37C, 5% CO2 for 18 hours, washed, incubated
with a secondary HRP labeled anti-IFN-gamma antibody or
anti-IL-4 antibody and developed by addition of TMB substrate.
Raw spot counts were recorded by a CTL S5 UV ELISPOT
reader. Results were recorded as the mean number of SFC over
background and adjusted to spots per one million cells seeded.
Responses to stimulations are considered positive if the number
of spots are: 1) at least twice greater than background, 2) greater
than 50 spot forming cells per one million splenocytes over back-
ground (i.e. one response over background per 20,000 spleno-
cytes), and 3) statistically significant by Wilcoxon Signed Rank
Test in comparison with the corresponding spot forming cell
data set for other groups (p < 0.05) using SigmaPlot software.
Immunization of HLA DR3 transgenic mice
Prior to each immunization, animals were anesthetized by IP
injection of ketamine (20mg/mL) and xylazine as previously
stated.
A control group of 8 HLA DR3 tg mice were immunized
intra-dermally with saline and Imject Alum adjuvant (Thermo-
Scientific, 77161) in 1:1 ratio for a total inoculation of 100 mL
on 3 occasions over 4 weeks (days 0, 14, 25).
A group of 9 HLA DR3 transgenic mice received intra-dermal
immunizations of 50 mg/100 mL of SGH with 50 mg/100 mL of
adjuvant on 3 occasions over 4 weeks (days 0, 14, 25).
A group of 8 HLA DR3 transgenic mice were immunized
intra-dermally with a pool of tick salivome predicted peptides, in
equal representation, and a 1:1 ratio of adjuvant for a total of
50 mg peptide/100 mL dose on 3 occasions over 4 weeks (days 0,
14, 25). This immunization arm was referred to as naked peptide
pool (NPP).
A group of 9 HLA DR3 transgenic mice received intradermal
immunizations of liposomal formulated peptides and an equal
volume of adjuvant in 100 mL on 3 occasions over 4 weeks (days
0, 14, 25). This immunization arm was referred to as peptide
pool in liposomes (LPP). Sterically stable cationic liposomes were
prepared from 3 lipid components: dioleylphosphatidylethanol-
amine (DOPE), dimethylaminoethane-carbamoyl-cholesterol
(DC-cholesterol), and polyethylene glycol 2000-phosphatidyl-
ethanolamine (PEG). The lipids were mixed in chloroform, dried
in a rotary evaporator, and re-suspended in phosphate-buffered
saline (PBS) to make empty multi-lamellar vesicles. These vesicles
were sonicated 5 times for 30 seconds each at 4C to convert
them into multi-lamellar liposomes. Multi-lamellar liposomes
(10 nmol) were mixed with peptides, flash frozen, and freeze-
dried overnight. To encapsulate peptides in liposomes, the
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resulting powder was re-suspended with sterile distilled water and
vortexed for 15 seconds every 5 minutes for 30 minutes at room
temperature. PBS was added to yield a final liposome concentra-
tion of 10mM lipid/mg peptides. Vesicles <150 nm in diameter
were produced by 20–30 cycles of extrusion through polycarbon-
ate filters using a Lipofast extruder (Avestin, Canada). Liposome
formulations were stored at 4C until use.
Cytokine profile detection of immunized HLA DR3 mice
At day 42, 4-5 mice from each immunization arm were eutha-
nized to determine the effect of immunizations on cytokine pro-
duction. The frequency of epitope-specific splenocytes was
determined by IL-4 ELISpot assay using methods as previously
stated with the following differences. Post immunization, spleens
were harvested from control immunization groups and groups of
HLA DR3 tg mice immunized to SGH, NPP and LPP. Cells
were enumerated and plated as previously stated. Cells were co-
cultured with SGH at 20 mg/mL in triplicate wells, pooled pepti-
des, PP (20 mg/mL) and individual peptides (20 mg/mL). Cells
stimulated with ConA (2 mg/ml) acted as positive controls while
cells stimulated with PBS (no peptide) served as negative con-
trols. ELISpot plates were incubated at 37C, 5% CO2 for
18 hours. Washing, detection and spot detection was completed
as previously stated. Positive response criteria for ELISpot analy-
sis remains as previously stated, however statistical significance is
determined by Kruskal-Wallis ANOVA of Variance on Ranks
with post-hoc Dunn’s test in comparison with the corresponding
spot forming cell data set for other groups (P < 0.05).
Additionally, cytokines were simultaneously monitored by
cytokine bead array (CBA) according to manufacturer’s speci-
fications using the BD Bioscience Th1/Th2/Th17 kit and
appropriate standards (BD Bioscience, 560485, 561665) for
detection of IL-10, IL-17A, TNF, IFN-gamma, IL-2, IL-4
and IL-6. Briefly, splenocytes were harvested from immunized
mice and transferred in triplicate to non-tissue culture, v-bot-
tom 96 well plates for stimulation with ConA (2 mg/mL),
PBS, SGH (20 mg/mL) and pooled peptides, PP (20 mg/
mL). Cells were incubated at 37C, 5% CO2 for 24, 48 and
72 hrs. Post incubation, plates were pelleted and supernatant
was collected and stored at ¡80C until the CBA assay was
performed. Cell supernatants from individual mice within
immunization arms and timepoints were combined for test-
ing. Supernatants were monitored for cytokine production
using an LSRII Flow Cytometer and analyzed using the FloJo
software. Cytokine production is presented as picogram per
mL values above background.
Borrelia challenge of immunized HLA DR3 Mice
Additionally on day 42, the remaining 4 mice from each
immunization arm were challenged with 3 Bb-infected nymphs
as previously stated. Infection status of each animal was deter-
mined 3 weeks post challenge, as previously stated to asses any
levels of protection afforded by immunization. qPCR-generated
Bb RecA gene copy number data were analyzed by Kruskal-
Wallis ANOVA of Variance on Ranks and the means compared
by Student-Newman-Keul’s test (P < 0.05) (SigmaPlot).
Disclosure of Potential Conflicts of Interest
Two of the contributing authors, Anne S. De Groot and Wil-
liam D. Martin, are senior officers and majority shareholders at
EpiVax, Inc., a privately owned biotechnology company located
in Providence, RI. Leonard Moise is employed by and holds
stock options in EpiVax. These authors acknowledge that there is
a potential conflict of interest related to their relationship with
EpiVax and attest that the work contained in this research report
is free of any bias that might be associated with the commercial
goals of the company.
Acknowledgments
The authors are grateful to Emily Troiano for dissection of
tick salivary glands, Jason LaPorte for assisting with tick infesta-
tions and Tori Deschenes for assistance with CBA. We also thank
Dr. Jose Ribeiro for his invaluable informatics assistance with the
tick salivome.
Funding
This work was supported by NIH U19 grant (AI082642) (to
A.D.G.). It is Contribution No. 5404 of the Rhode Island Agri-
culture Experiment Station. The content is solely the responsibil-
ity of the authors and does not necessarily represent the official
views of the National Institute of Allergy and Infectious Diseases
or the National Institutes of Health.
References
1. Sonenshine D. Biology of Ticks. New York: Oxford
University Press, 1991.
2. Balashov IS. A translation of Bloodsucking ticks (Ixo-
doidea)–vectors of diseases of man and animals. College
Park, MD: Entomological Society of America, 1972.
3. Barbour AG, Fish D. The biological and social phe-
nomenon of Lyme disease. Science (New York, NY)
1993; 260:1610–6; http://dx.doi.org/10.1126/science.
8503006
4. Mather TN, Mather ME. Intrinsic competence of three
ixodid ticks (Acari) as vectors of the Lyme disease spiro-
chete. JMed Entomol 1990; 27:646-50; PMID:2388239
5. Gern L. Life cycle of Borrelia burgdorferi sensu lato and
transmission to humans. Curr Prob Dermatol 2009;
37:18-30; PMID:19367095; http://dx.doi.org/10.
1159/000213068
6. van der Burg SH, Bijker MS, Welters MJP, Offringa R,
Melief CJM. Improved peptide vaccine strategies, cre-
ating synthetic artificial infections to maximize immune
efficacy. Adv Drug Deliv Rev 2006; 58:916-30;
PMID:16979788; http://dx.doi.org/10.1016/j.addr.
2005.11.003
7. Piesman J, Mather TN, Sinsky RJ, Spielman A. Dura-
tion of tick attachment and Borrelia burgdorferi trans-
mission. J Clin Microbiol 1987; 25:557-8;
PMID:3571459
8. Allen JR. Tick resistance: basophils in skin reactions of
resistant guinea pigs. Int J Parasitol 1973; 3:195-200;
PMID:4706571; http://dx.doi.org/10.1016/0020-
7519(73)90024-6
9. Askenase PW, Bagnall BG, Worms MJ. Cutaneous
basophil-associated resistance to ectoparasites (ticks).
I. Transfer with immune serum or immune cells.
Immunology 1982; 45:501-11; PMID:7061108
10. Krause PJ, Grant-Kels JM, Tahan SR, Dardick KR,
Alarcon-Chaidez F, Bouchard K, Visini C, Deriso C,
Foppa IM, Wikel S. Dermatologic changes induced by
repeated Ixodes scapularis bites and implications for
prevention of tick-borne infection. Vector Borne Zoo-
notic Dis 2009; 9:603-10; PMID:19196014; http://dx.
doi.org/10.1089/vbz.2008.0091
11. Brown SJ, Askenase PW. Immune rejection of ectopar-
asites (ticks) by T cell and IgG1 antibody recruitment
of basophils and eosinophils. Fed Proc 1983; 42:1744-
9; PMID:6601034
12. Nadif R, Zerimech F, Bouzigon E, Matran R. The role
of eosinophils and basophils in allergic diseases
3058 Volume 10 Issue 10Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
1:1
4 0
8 O
cto
be
r 2
01
5 
considering genetic findings. Curr Opin Allergy Clin
Immunol 2013; 13:507-13; PMID:23974679; http://
dx.doi.org/10.1097/ACI.0b013e328364e9c0
13. Bowman A, Nuttall P, eds. Ticks: Biology, Disease and
Control: Cambridge University Press, 2008; 186-204.
14. Burke G, Wikel SK, Spielman A, Telford SR, McKay
K, Krause PJ. Hypersensitivity to ticks and Lyme dis-
ease risk. Emer Infect Dis 2005; 11:36-41;
PMID:15705320
15. Nazario S, Das S, de Silva AM, Deponte K, Marcanto-
nio N, Anderson JF, Fish D, Fikrig E, Kantor FS. Pre-
vention of Borrelia burgdorferi transmission in guinea
pigs by tick immunity. Am J Trop Med Hyg 1998;
58:780-5; PMID:9660463
16. Schoeler GB, Manweiler SA, Wikel SK. Ixodes scapula-
ris: effects of repeated infestations with pathogen-free
nymphs on macrophage and T lymphocyte cytokine
responses of BALB/c and C3H/HeN mice. Exp Parasi-
tol 1999; 92:239-48; PMID:10425152; http://dx.doi.
org/10.1006/expr.1999.4426
17. Xu Q, Seemanapalli SV, Reif KE, Brown CR, Liang
FT. Increasing the recruitment of neutrophils to the
site of infection dramatically attenuates Borrelia burg-
dorferi infectivity. J Immunol (Baltimore, Md: 1950)
2007; 178:5109-15; PMID:17404293; http://dx.doi.
org/10.4049/jimmunol.178.8.5109
18. Gonzalez-Galarza FF CS, Middleton D, Jones AR.
Allele frequency net: a database and online repository
for immune gene frequencies in worldwide popula-
tions. Nucleic Acid Res 2011; 39: D913-9;
PMID:21062830; http://dx.doi.org/10.1093/nar/
gkq1128
19. Kurtenbach K, Hanincova K, Tsao JI, Margos G, Fish
D, Ogden NH. Fundamental processes in the evolu-
tionary ecology of Lyme borreliosis. Nat Rev Micro
2006; 4:660-9; PMID:16894341; http://dx.doi.org/
10.1038/nrmicro1475
20. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM,
Gonzalez MA, Martin W, Saint-Aubin C. From
genome to vaccine: in silico predictions, ex vivo verifi-
cation. Vaccine 2001; 19:4385-95; PMID:11483263;
http://dx.doi.org/10.1016/S0264-410X(01)00145-1
21. Ribeiro JM, Alarcon-Chaidez F, Francischetti IM,
Mans BJ, Mather TN, Valenzuela JG, Wikel SK. An
annotated catalog of salivary gland transcripts from Ixo-
des scapularis ticks. Insect Biochem Mol Biol 2006;
36:111-29; PMID:16431279; http://dx.doi.org/
10.1016/j.ibmb.2005.11.005
22. Francischetti IM, Mather TN, Ribeiro JM. Cloning of
a salivary gland metalloprotease and characterization of
gelatinase and fibrin(ogen)lytic activities in the saliva of
the Lyme disease tick vector Ixodes scapularis. Biochem
Biophys Res Commun 2003; 305:869-75;
PMID:12767911; http://dx.doi.org/10.1016/S0006-
291X(03)00857-X
23. Maritz-Olivier C, Stutzer C, Jongejan F, Neitz AWH,
Gaspar ARM. Tick anti-hemostatics: targets for future
vaccines and therapeutics. Trends Parasitol 2007;
23:397-407; PMID:17656153; http://dx.doi.org/
10.1016/j.pt.2007.07.005
24. Moise L, Terry F, Ardito M, Tassone R, Latimer H,
Boyle C, Martin WD, De Groot AS. Universal H1N1
influenza vaccine development: identification of con-
sensus class II hemagglutinin and neuraminidase epito-
pes derived from strains circulating between 1980 and
2011. Hum Vaccines Immunother 2013; 9:1598-607;
PMID:23846304; http://dx.doi.org/10.4161/hv.25598
25. Moise L, Tassone R, Latimer H, Terry F, Levitz L,
Haran JP, Ross TM, Boyle CM, Martin WD, De
Groot AS. Immunization with cross-conserved H1N1
influenza CD4C T-cell epitopes lowers viral burden in
HLA DR3 transgenic mice. Hum Vaccines Immun-
other 2013; 9:2060-8; PMID:24045788; http://dx.doi.
org/10.4161/hv.26511
26. De Groot AS, Martin W. Reducing risk, improving
outcomes: bioengineering less immunogenic protein
therapeutics. Clin Immunol (Orlando, Fla) 2009;
131:189-201; PMID:19269256; http://dx.doi.org/
10.1016/j.clim.2009.01.009
27. Trager W. Acquired immunity to ticks. J Parasitol
1939; 25:57-81; http://dx.doi.org/10.2307/3272160
28. Wikel SK. Host immunity to ticks. Annu Rev Entomol
1996; 41:1-22; PMID:8546443; http://dx.doi.org/
10.1146/annurev.en.41.010196.000245
29. Heinze DM, Wikel SK, Thangamani S, Alarcon-Chai-
dez FJ. Transcriptional profiling of the murine cutane-
ous response during initial and subsequent infestations
with Ixodes scapularis nymphs. Parasit Vectors 2012;
5:26; PMID:22309607; http://dx.doi.org/10.1186/
1756-3305-5-26
30. Mejri N, Franscini N, Rutti B, Brossard M. Th2 polari-
zation of the immune response of BALB/c mice to Ixo-
des ricinus instars, importance of several antigens in
activation of specific Th2 subpopulations. Parasite
Immunol 2001; 23:61-9; PMID:11240897; http://dx.
doi.org/10.1046/j.1365-3024.2001.00356.x
31. Ferreira BR, Silva JS. Successive tick infestations selec-
tively promote a T-helper 2 cytokine profile in mice.
Immunology 1999; 96:434-9; PMID:10233725;
http://dx.doi.org/10.1046/j.1365-2567.1999.00683.x
32. Schoeler GB, Manweiler SA, Wikel SK. Cytokine
responses of C3H/HeN mice infested with Ixodes scap-
ularis or Ixodes pacificus nymphs. Parasite Immunol
2000; 22:31-40; PMID:10607289; http://dx.doi.org/
10.1046/j.1365-3024.2000.00272.x
33. Borsky I, Hermanek Jı, Uhlır J, Dusbabek Fe. Humoral
and cellular immune response of BALB/c mice to
repeated infestations with Ixodes ricinus nymphs. Int J
Parasitol 1994; 24:127-32; PMID:8021100; http://dx.
doi.org/10.1016/0020-7519(94)90066-3
34. Mbow ML, Christe M, Rutti B, Brossard M. Absence
of acquired resistance to nymphal Ixodes ricinus ticks
in BALB/c mice developing cutaneous reactions. J Para-
sitol 1994; 80:81-7; PMID:8308662; http://dx.doi.
org/10.2307/3283349
35. Christe M, Rutti B, Brossard M. Influence of the genetic
background and parasite load of mice on the immune
response developed against nymphs of Ixodes ricinus. Par-
asitol Res 1999; 85:557-61; PMID:10382605; http://dx.
doi.org/10.1007/s004360050595
36. Narasimhan S, Deponte K, Marcantonio N, Liang X,
Royce TE, Nelson KF, Booth CJ, Koski B, Anderson
JF, Kantor F, et al. Immunity against Ixodes scapularis
salivary proteins expressed within 24 hours of attach-
ment thwarts tick feeding and impairs Borrelia trans-
mission. PloS One 2007; 2:e451; PMID:17505544;
http://dx.doi.org/10.1371/journal.pone.0000451
37. Bechara GH, SzaboMP,Mukai LS, Rosa PC. Immunisa-
tion of dogs, hamsters and guinea pigs against Rhipice-
phalus sanguineus using crude unfed adult tick extracts.
Vet Parasitol 1994; 52:79-90; PMID:8030191; http://dx.
doi.org/10.1016/0304-4017(94)90038-8
38. Titus RG, Bishop JV, Mejia JS. The immunomodula-
tory factors of arthropod saliva and the potential for
these factors to serve as vaccine targets to prevent patho-
gen transmission. Parasite Immunol 2006; 28:131-41;
PMID:16542315
39. Ferreira BR, Silva JS. Saliva of Rhipicephalus sangui-
neus tick impairs T cell proliferation and IFN-
g-induced macrophage microbicidal activity. Vet
Immunol Immunopathol 1998; 64:279-93;
PMID:9730222; http://dx.doi.org/10.1016/S0165-
2427(98)00135-4
40. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F,
Leng Q, Abdel Hady KM, Verberkmoes NC, Sztein
MB, Losikoff PT, Martin WD, et al. The two-faced T
cell epitope: examining the host-microbe interface with
JanusMatrix. Hum Vaccines Immunother 2013;
9:1577-86; PMID:23584251; http://dx.doi.org/
10.4161/hv.24615
41. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Wei-
ner DB, Martin W, De Groot AS. VennVax, a DNA-
prime, peptide-boost multi-T-cell epitope poxvirus vac-
cine, induces protective immunity against vaccinia
infection by T cell response alone. Vaccine 2011;
29:501-11; PMID:21055490; http://dx.doi.org/
10.1016/j.vaccine.2010.10.064
42. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J,
Rogers AB, Martin W, De Groot AS. HelicoVax: epi-
tope-based therapeutic Helicobacter pylori vaccination
in a mouse model. Vaccine 2011; 29:2085-91;
PMID:21236233; http://dx.doi.org/10.1016/j.vaccine.
2010.12.130
43. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci
O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP,
Sinigaglia F, et al. Generation of tissue-specific and
promiscuous HLA ligand databases using DNA micro-
arrays and virtual HLA class II matrices. Nat Biotech-
nol 1999; 17:555-61; PMID:10385319; http://dx.doi.
org/10.1038/9858
44. Bond KB, Sriwanthana B, Hodge TW, De Groot AS,
Mastro TD, Young NL, Promadej N, Altman JD, Lim-
pakarnjanarat K, McNicholl JM. An HLA-directed
molecular and bioinformatics approach identifies new
HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte
epitopes in HIV-1-infected Thais. AIDS Res Hum Ret-
rov 2001; 17:703-17; PMID:11429111; http://dx.doi.
org/10.1089/088922201750236988
45. Dong Y, Demaria S, Sun X, Santori FR, Jesdale BM,
De Groot AS, Rom WN, Bushkin Y. HLA-A2-
restricted CD8C-cytotoxic-T-cell responses to novel
epitopes in Mycobacterium tuberculosis superoxide dis-
mutase, alanine dehydrogenase, and glutamine synthe-
tase. Infect Immun 2004; 72:2412-5;
PMID:15039371; http://dx.doi.org/10.1128/IAI.72.
4.2412-2415.2004
46. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW,
Nepom GT, Baxter-Lowe LA. Antibiotic-refractory
Lyme arthritis is associated with HLA-DR molecules
that bind a Borrelia burgdorferi peptide. J Exp Med
2006; 203:961-71; PMID:16585267; http://dx.doi.
org/10.1084/jem.20052471
47. Southwood S, Sidney J, Kondo A, del Guercio MF,
Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey
HM, Sette A. Several common HLA-DR types share
largely overlapping peptide binding repertoires. J
Immunol (Baltimore, Md: 1950) 1998; 160:3363-73;
PMID:9531296
48. Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J,
Strauss G, H€ammerling GJ, David CS. HLA-DRB1
polymorphism determines susceptibility to autoim-
mune thyroiditis in transgenic mice: definitive associa-
tion with HLA-DRB1*0301 (DR3) gene. J Exp Med
1996; 184:1167-72; PMID:9064334; http://dx.doi.
org/10.1084/jem.184.3.1167
49. Strauss G, Vignali DA, Schonrich G, Hammerling GJ.
Negative and positive selection by HLA-DR3(DRw17)
molecules in transgenic mice. Immunogenetics 1994;
40:104-8; PMID:8026858
50. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur
M, Benoist C, Mathis D. Mice lacking MHC class II
molecules. Cell 1991; 66:1051-66; PMID:1909605;
http://dx.doi.org/10.1016/0092-8674(91)90448-8
51. Nabozny GH, Baisch JM, Cheng S, Cosgrove D, Grif-
fiths MM, Luthra HS, David CS. HLA-DQ8 trans-
genic mice are highly susceptible to collagen-induced
arthritis: a novel model for human polyarthritis. J Exp
Med 1996; 183:27-37; PMID:8551230; http://dx.doi.
org/10.1084/jem.183.1.27
52. Yang L, Weis JH, Eichwald E, Kolbert CP, Persing
DH, Weis JJ. Heritable susceptibility to severe Borrelia
burgdorferi-induced arthritis is dominant and is associ-
ated with persistence of large numbers of spirochetes in
tissues. Infect Immun 1994; 62:492-500;
PMID:8300208
53. Morrison TB, Ma Y, Weis JH, Weis JJ. Rapid and sen-
sitive quantification of borrelia burgdorferi-infected
mouse tissues by continuous fluorescent monitoring of
PCR. J Clin Microbiol 1999; 37:987-92;
PMID:10074514
www.landesbioscience.com 3059Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
1:1
4 0
8 O
cto
be
r 2
01
5 
